A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells

Molecular Cancer Research

Volumn 7, Issue 3, 2009, Pages 402-414

  Hua, Guoqiang ^a,b,e   Zhu, Bing ^a,b,c   Rosa, Fréderic ^a,b,e   Deblon, Nicolas ^a,b,d   Adélaïde, José ^a,b   Kahn Perlès, Brigitte ^a,b,e   Birnbaum, Daniel ^a,b   Imbert, Jean ^a,b,e  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e Aix Marseille university   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 4;

ANGIOGENESIS; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; ENHANCER REGION; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEART DEVELOPMENT; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REGULATORY MECHANISM; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CONSERVED SEQUENCE; FEEDBACK, BIOCHEMICAL; GATA4 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

MAMMALIA;

EID: 61849157036     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0175     Document Type: Article

References (58)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
3. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-38.
4. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15.
5. Pugatsch T, Abedat S, Lotan C, Beeri R. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 2006; 8:R36.
6. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605-10.
7. Hurst HC. Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001;3: 395-8.
8. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89:899-906.
9. Li M, Wang Y, Hung MC, Kannan P. Inefficient proteasomal-degradation pathway stabilizes AP-2A and activates HER-2/neu gene in breast cancer. Int J Cancer 2006;118:802-11.
10. Zuo T, Wang L, Morrison C, et al. FOXP3is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007;129:1275-86.
11. Nezu M, Sasaki H, Kuwahara Y, et al. Identification of a novel promoter and exons of the c-ERBB-2 gene. Biochem Biophys Res Commun 1999;258: 499-505.
12. Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 2005;280:24428-34.
13. Delacroix L, Begon D, Chatel G, Jackers P, Winkler R. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol 2005;24:582-94.
14. Vernimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 2003;370:323-9.
15. Ishii S, Imamoto F, Yamanashi Y, Toyoshima K, Yamamoto T. Characterization of the promoter region of the human c-erbB-2 protooncogene. Proc Natl Acad Sci U S A 1987;84:4374-8.
16. Tal M, King CR, Kraus MH, Ullrich A, Schlessinger J, Givol D. Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. Mol Cell Biol 1987;7:2597-601.
17. Xing X, Wang SC, Xia W, et al. The ets protein PEA3suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000;6:189-95.
18. Grooteclaes M, Vernimmen D, Plaza S, Pasleau F, Hodzic D, Winkler-Gol R. A new cis element is involved in the HER2 gene overexpression in human breast cancer cells. Cancer Res 1999;59:2527-31.
19. Bates NP, Hurst HC. An intron 1 enhancer element mediates oestrogeninduced suppression of ERBB2 expression. Oncogene 1997;15:473-81.
20. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996; 13:1701-7.
21. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci U S A 1995;92:744-7.
22. Scott GK, Chang CH, Erny KM, et al. Ets regulation of the erbB2 promoter. Oncogene 2000;19:6490-502.
23. Bates NP, Hurst HC. Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland. J Mammary Gland Biol Neoplasia 1997;2: 153-63.
24. Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum D. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 2003;103:565-71.
25. Bertucci F, Borie N, Ginestier C, et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004;23: 2564-75.
26. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004;59:1-12.
27. Kuo CT, Morrisey EE, Anandappa R, et al. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 1997;11: 1048-60.
28. Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 1997;11:1061-72.
29. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 2001;21:7460-9.
30. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
31. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 2002;30:e48.
32. Park PJ, Cao YA, Lee SY, et al. Current issues for DNA microarrays: platform comparison, double linear amplification, and universal RNA reference. J Biotechnol 2004;112:225-45.
33. Grooteclaes M, Pasleau F, Dijkmans H, Berzi P, Albert A, Winkler-Gol R. The 6-kilobase c-erbB2 promoter contains positive and negative regulatory elements functional in human mammary cell lines. Cancer Res 1994;54:4193-9.
34. Fluck CE, Miller WL. GATA-4 and GATA-6 modulate tissue-specific transcription of the human gene for P450c17 by direct interaction with Sp1. Mol Endocrinol 2004;18:1144-57.
35. Yeh JH, Lecine P, Nunes JA, et al. Novel CD28-responsive enhancer activated by CREB/ATF and AP-1 families in the human interleukin-2 receptor achain locus. Mol Cell Biol 2001;21:4515-27.
36. Yamagata T, Nishida J, Sakai R, et al. Of the GATA-binding proteins, only GATA-4 selectively regulates the human interleukin-5 gene promoter in interleukin-5-producing cells which express multiple GATA-binding proteins. Mol Cell Biol 1995;15:3830-9.
37. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-9.
38. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
39. Todorovic-Rakovic N, Jovanovic D, Neskovic-Konstantinovic Z, Nikolic- Vukosavljevic D. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer. Pathol Int 2005; 55:318-23.
40. Cantor AB, Orkin SH. Coregulation of GATA factors by the friend of GATA (FOG) family of multitype zinc finger proteins. Semin Cell Dev Biol 2005;16: 117-28.
41. Svensson EC, Tufts RL, Polk CE, Leiden JM. Molecular cloning of FOG-2: a modulator of transcription factor GATA-4 in cardiomyocytes. Proc Natl Acad Sci U S A 1999;96:956-61.
42. Johnson KD, Boyer ME, Kang JA, Wickrema A, Cantor AB, Bresnick EH. Friend of GATA-1-independent transcriptional repression: a novel mode of GATA-1 function. Blood 2007;109:5230-3.
43. Mao C, Tai WC, Bai Y, Poizat C, Lee AS. In vivo regulation of Grp78/BiP transcription in the embryonic heart: role of the endoplasmic reticulum stress response element and GATA-4. J Biol Chem 2006;281:8877-87.
44. Antoniv TT, Tanaka S, Sudan B, et al. Identification of a repressor in the first intron of the human a2(I) collagen gene (COL1A2). J Biol Chem 2005;280: 35417-23.
45. Wang L, Tanaka S, Ramirez F. GATA-4 binds to an upstream element of the human a2(I) collagen gene (COL1A2) and inhibits transcription in fibroblasts. Matrix Biol 2005;24:333-40.
46. Murakami A, Ishida S, Dickson C. GATA-4 interacts distinctively with negative and positive regulatory elements in the Fgf-3promoter . Nucleic Acids Res 2002;30:1056-64.
47. Amin DN, Perkins AS, Stern DF. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 2004;23:1428-38.
48. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25.
49. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005;5:163-71.
50. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 2004;101:6975-80.
51. Patient RK, McGhee JD. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev 2002;12:416-22.
52. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 1993;53: 627-35.
53. Theillet C, Adelaide J, Louason G, et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 1993;7:219-26.
54. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDC(T)) method. Methods 2001;25: 402-8.
55. Chen Y, Gill GN. Positive and negative regulatory elements in the human erbB-2 gene promoter. Oncogene 1994;9:2269-76.
56. Hudson LG, Ertl AP, Gill GN. Structure and inducible regulation of the human c-erb B2/neu promoter. J Biol Chem 1990;265:4389-93.
57. Scott GK, Daniel JC, Xiong X, Maki RA, Kabat D, Benz CC. Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J Biol Chem 1994;269: 19848-58.
58. Balda MS, Matter K. The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression. EMBO J 2000; 19:2024-33.